iFabric Corp. Earnings Call Signals Growth With Strains

iFabric Corp. ((TSE:IFA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Record results and bullish guidance framed iFabric Corp.’s latest earnings call as cautiously optimistic. Management highlighted 20% revenue growth, a strong start to fiscal 2026 and expanding retail programs, while acknowledging margin compression, elevated inventory and tariff-related noise that will test execution in the near term.

Record Revenue Growth in Fiscal 2025

Fiscal 2025 revenue climbed to $32.9 million from $27.3 million, a 20% year‑over‑year increase that management linked to multiple retail programs and new product launches. Q4 2025 revenue hit a record $11.0 million, up 5% versus the prior year’s $10.5 million, underscoring solid momentum exiting the fiscal year.

Q1 2026 Guidance and Walmart-Driven Surge

For Q1 2026, iFabric guided to a striking $25–$27 million in revenue, nearly matching full‑year 2025 sales in a single quarter. The surge is powered by scrubs expansion to about 1,367 Walmart stores, broader scrubs styles, and other large retailer launches, with the 52‑week replenishment model pointing to recurring, non‑seasonal demand.

Intimates Brand Transition and Margin Potential

The company chose not to renew its Maidenform license and instead launched its own intimate apparel brand, eliminating roughly 10% royalty and advertising fees. Management said the new line is already outperforming the prior licensed brand, and with intimates carrying mid‑40s to low‑50s gross margins, this shift is a key lever for future blended margin recovery.

Tariff Reset and Prospective Refund

Tariffs that had weighed heavily on U.S. sales were revised down to a more manageable 10%, easing a major margin headwind. iFabric is also pursuing a refund claim of about $600,000 U.S. on previously charged tariffs, and management expects this clarity to support improved pricing and profitability once processes catch up.

Stronger Cash and Inventory Built for Growth

Cash rose to $3.8 million from $2.1 million year over year, while inventories more than doubled to $21.0 million from $10.1 million. Management described the inventory build as deliberate, positioning the company to reliably service the large Q1 cadence and major retail rollouts without missing shelf openings.

Clinical Validation and Product Differentiation

iFabric underscored that its scrubs and underlying technology are backed by peer‑reviewed clinical trial data, providing a rare evidence‑based edge on retail shelves. The company is leveraging this clinical story to pursue additional channels such as hospitals, hospitality and travel, viewing these as meaningful longer‑term growth vectors.

Scaling Investments and EBITDA Ambitions

Management highlighted one‑time investments in ERP systems and operations, with total ERP spend around $0.5 million and most incurred in 2025 to support scaling. Despite the near‑term hit, the company is targeting adjusted EBITDA margins of roughly 15% in 2026 and up to 20% in 2027 as revenue grows and these one‑off costs roll off.

Sharp Gross Margin Compression

The downside of 2025’s growth story was margin, with full‑year gross margin sliding to 32% from 41% and Q4 margin dropping to 26% from about 40% a year earlier. Management blamed higher tariffs, a temporary pause in intimate apparel shipments and aggressive promotional spending to secure shelf space, but expects a rebound as these pressures ease.

Adjusted EBITDA Under Pressure

Adjusted EBITDA declined to $1.9 million in 2025 from $2.7 million in 2024, reflecting the squeeze from lower gross margins and one‑time operating expenses. Management cast this as a transition year, arguing that investments made in systems and branding should translate into stronger profitability as volumes and mix improve.

Working Capital Tied Up in Inventory

The inventory ramp to $21.0 million from $10.1 million represents a major working capital commitment designed to support big‑box shipments. To fund this build, the company drew about $6.7 million on its credit facility even as it held more cash in U.S. dollars for foreign‑exchange reasons, a stance that puts a spotlight on near‑term balance‑sheet discipline.

Revenue Timing Noise From Late Shipments

A roughly $1.0 million shipment to Costco in late December failed to meet the retailer’s warehouse‑receipt cutoff, pushing revenue recognition into Q1 and muting Q4 reported sales. Management stressed that this was a timing issue rather than a demand problem, creating some quarter‑to‑quarter volatility that should normalize.

Tariff Refund Delays and Residual Exposure

While the legal shift in tariffs is positive, iFabric acknowledged that the timing of the roughly $600,000 U.S. refund is uncertain amid administrative backlogs. Prior tariff impacts on about $17 million of U.S. sales still weigh on historical margins, and full relief will take time to work through contracts and pricing.

Supply Chain and Geopolitical Risk

The company remains heavily reliant on Chinese fabric suppliers, leaving it exposed to geopolitical tensions and any renewed tariff shocks. Management is working to diversify production into Vietnam, Bangladesh and India, but cautioned that realistic retooling and qualification timelines span three to five years.

Regulatory and Commercialization Hurdles

Some regulatory steps, including certain EPA‑related claims and leaching studies, are still in process, creating uncertainty around timing for enhanced product claims. In parallel, high‑potential channels such as defense and hospital markets offer attractive upside but involve long sales cycles and complex approval paths that could delay revenue.

Short-Term Operating Cost Pressures

Selling and administrative expenses rose by about $1 million in 2025, reflecting royalties, ERP implementation and other scaling costs that hit the income statement. Management framed many of these as one‑off or variable in nature, suggesting expense growth should lag revenue as the business matures.

Guidance and Outlook

Looking ahead, iFabric’s Q1 2026 outlook of $25–$27 million signals a step‑change in scale, supported by Walmart expansion, expanded SKUs, ongoing scrubs replenishment and Roots shipments. Management’s medium‑term plan hinges on margin repair via higher‑margin intimates, improved mix, lower royalties and normalized tariffs, with targeted adjusted EBITDA margins of about 15% in 2026 and 20% in 2027.

iFabric’s earnings call painted a company in acceleration mode, pairing record revenue and robust near‑term guidance with candid acknowledgment of margin and working‑capital strains. For investors, the story now rests on management’s ability to convert this retail expansion and clinical edge into sustainable, higher‑margin growth while navigating tariff, supply chain and regulatory risks.